低剂量他莫西芬用于预防乳腺癌:现实世界的经验
Rima Patel1, Cao Jin2, Diana Jaber3
1Department of Medicine, Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY.
Clinical breast cancer
|January 21, 2025
概括
低剂量他莫西芬 (LDT) 化疗预防被19%的患有高风险病变的妇女使用. 与管道癌 in situ (DCIS) 相比,LDT在异型增生和局部叶状癌 (LCIS) 病例中的吸收率更高.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 自2019年推出以来,对低剂量他莫西芬 (LDT) 用于乳腺癌化学预防的数据有限.
- 评估LDT吸收和相关因素对于指导临床实践至关重要.
研究的目的:
- 确定该机构中用于化疗预防的LDT吸收率.
- 为了识别与LDT使用相关的患者和疾病特征.
主要方法:
- 对477名被诊断患有局部管道癌 (DCIS),局部叶状癌 (LCIS) 或异常增生 (2019-2021) 的妇女进行了回顾性图表审查.
- 记录-二项式模型比较标准剂量他莫西芬 (SDT) 与LDT使用.
- 分析的零膨胀波桑回归分析了不良事件 (AE) 率.
主要成果:
- 19% (N=89) 的患者开始LDT;27% (N=129) 开始SDT;20% (N=95) 拒绝治疗.
- 与DCIS (17.4%) 相比,LCIS或非典型增多症患者 (31.4%) 的LDT使用率更高.
- 与SDT (1.9/1000天) 相比,LDT (1.3/1000天) 的AE发病率更高,尽管AE的总体频率没有显著差异.
结论:
- 19%的患有高风险病变的妇女开始使用LDT进行化疗预防,而患有非典型病变和/或LCIS的妇女更容易接受.
- 在高风险病变的符合条件的妇女中,LDT是化疗预防的可行选择.
- 医生应考虑为有高风险病变的符合条件的妇女提供LDT.
关键词:
不典型的增生症 (atypical hyperplasia) 是一种不典型的增生症.化学预防 化学预防在位管道癌 (DCIS)在位的叶状癌 (LCIS)塔莫西芬 (Tamoxifen) 是一种更多相关视频
11:38Voluntary Breath-hold Technique for Reducing Heart Dose in Left Breast Radiotherapy
Published on: July 3, 2014
46.7K
19:44Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
Published on: May 30, 2012
18.7K
相关概念视频
Cancer Prevention
6.0K
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Some...
6.0K
Dose-Response Relationship: Overview
2.9K
Agonists can bind with and activate receptors, resulting in the formation of drug-receptor complexes. Once formed, these complexes catalyze many biochemical processes at the cellular level and subsequently induce a pharmacologic response. The degree of response is directly proportional to the fraction of activated receptors, which in turn, depends on the concentration of the drug at the receptor site as well as the sensitivity of the receptor. An increase in the administered dose contributes to...
2.9K
Hazard Ratio
81
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
81
Dose-Response Relationship: Potency and Efficacy
4.2K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
4.2K
